Splet16. apr. 2024 · Committed to world-class science! Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, … SpletCT or MRI and radionuclide bone imaging will be used to assess response according to Prostate Cancer Working Group 3 (PCWG3)–modified RECIST v1.1 by blinded independent central review (BICR) Q12W from the date of randomization. Imaging will continue until the end of treatment and will resume Q12W during the posttreatment period.
Study of Pembrolizumab (MK-3475) Combination Therapies in …
Splet02. jun. 2024 · Objectives: Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) and modified RECIST (mRECIST) are commonly used to assess tumour … Splet29. jan. 2024 · Warcraft 3: Reforged came out yesterday, and fans are not happy. This is a bit more complicated than your run-of-the-mill “people are angry on the internet” situation, … gma 35 software version
Trial Design and Objectives for Castration-Resistant …
SpletSecondary end points: rPFS per PCWG3-modified RECIST v1.1, DCR, DOR, and OS. Results One hundred three patients were treated. Median (range) age was 70.0 (46–89) years, 30.1% were PD-L1+, 35.9% had RECIST-measurable disease, 18.4% had visceral disease, and 26.2% had previously received enzalutamide only. Splet01. jun. 2024 · b Per modified RECIST/PCWG3 criteria; includes patients who had measurable disease at baseline per the investigator and ≥16 weeks of follow-up. c Proportion of patients without radiographic progression per RECIST/PCWG3 criteria who were ongoing with treatment at 6 months. Splet05. jul. 2024 · Introduction RECIST is a standard way to measure the response of a tumor to treatment. CT is the preferred modality for the baseline study. The baseline scan should … gma3600bst monitor type